Sanofi to acquire Blueprint Medicines

Sanofi will pay $129.00 per share in cash and one CVR which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR

Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.

https://www.globenewswire.com/news-release/2025/06/02/3091539/0/en/Press-Release-Sanofi-to-acquire-Blueprint-Medicines-expanding-portfolio-in-rare-immunological-disease-and-adding-early-stage-pipeline-in-immunology.html

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint.

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, Blueprint’s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi’s growing immunology pipeline.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808

Rothko Merger Sub, Inc. an indirect wholly owned subsidiary of SANOFI, is offering to purchase all of the outstanding common shares of Blueprint Medicines Corporation for $129.00 per share in cash, without interest and subject to any withholding of taxes required by applicable legal requirements, plus one non-transferable contingent value right (CVR) per share, representing the right to receive contingent payments of up to an aggregate amount of $6.00 per share in cash, without interest, upon the achievement of one or both of the milestones on or prior to the expiration of the applicable milestone period set forth in the Contingent Value Rights Agreement, to be entered into with a rights agent mutually agreeable to Aventis Inc., a wholly owned subsidiary of SANOFI. Please see page 62 of the offer material for further details on the CVR Agreement.

• $2 per share, conditioned upon the achievement of a clinical development milestone for BLU-808, and

• $4 per share, conditioned upon the achievement of a regulatory milestone for BLU-808.

All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.